More insights.
More insights.
Subscribe to our newsletter.
Deep dives into design thinking, creative process, and the intersection of business and aesthetics.
Clinical Rationale, Real Results
Global guidelines are clear: when agitation or psychosis appears in dementia, start with non-pharmacological care. Person-centred routines, activity, and pain review are safer first steps than sedatives. Both NICE and the APA set this order of operations, reserving antipsychotics for crisis cases. And family safety matters.
WHELD, a large UK cluster-RCT, trained staff in person-centred care and daily meaningful activity. Over nine months it improved quality of life and reduced agitation versus usual care, and did so at lower cost—small effects, big implications: better days without extra spend, and a model designed for real homes.
Beyond staff training sits Cognitive Stimulation Therapy. Across trials, CST improves cognition and quality of life, and classic economic work shows high probability of cost-effectiveness versus usual care. Maintenance CST extends gains, with cost-utility signals especially when combined with standard dementia drugs.
The safety argument is strong. Antipsychotics offer modest benefits in the short run, yet meta-analyses and regulators link them to higher mortality in older adults with dementia. The FDA’s black-box warning reshaped practice, pushing teams toward psychosocial approaches and tighter review before any prescription.
Single-modality arts therapies show mixed results for agitation, but depression often lifts and engagement rises. The most dependable signal comes when programmes combine person-centred activity, social interaction, exercise, and review. That is where agitation falls and daily life steadies without chemical restraint.
From Care to Contracts
To turn care into contracts, measure what matters. Track antipsychotic days, night episodes, CMAI agitation scores, and transfer rates. The WHELD trial demonstrated quality-of-life gains and cost savings; national evidence summaries reach the same verdict. Those metrics anchor payer pilots and scale partnerships.
Economic reviews now converge: among non-drug options, maintenance CST shows the strongest cost-effectiveness signal, with classic CST already cost-effective in early work. These are not boutique findings; they appear across community and care-home settings and map cleanly onto payer value frameworks.
Digital delivery widens access. iWHELD’s remote coaching and virtual CST groups proved feasible and beneficial in pilots, helping homes recover capacity after COVID and letting families join routines across borders. The intervention is still the same; distance simply disappears behind structured video and guidance.
Tele-assessment supports the layer above care: when speech, mood, or memory changes, validated remote tools let teams triage early. Reliable teleneuropsychology and simple remote scales cut travel and delay, keeping people in rhythm while clinicians decide if a clinic visit or medication review is truly needed.
The investor lens is straightforward. Dementia prevalence is rising toward 150+ million by 2050 and economic burden toward trillions. Programmes that deliver calmer days with fewer drugs reduce total episode costs. When those outcomes are auditable, they become investable—and contractable—at system level.
Building the Asset Class with Nayuran
Nayuran packages the evidence into an operating system. The Method blends CST blocks, movement and music, sensory cues, and family rituals; the Institute trains teams; dashboards log medication days, night episodes, and mood. Outcome language becomes daily practice, not a poster on a wall.
On the floor, caregivers run short, repeatable cycles: ten-minute social prompts, shaded walking loops, evening wind-downs, and weekly antipsychotic reviews with physicians. The point is steadiness, not heroics. Fewer crises mean calmer rosters and fewer transfers, which payers recognise as real savings.
Digital by default, human at the core: Memory Capsules and scheduled video rituals keep relatives present and staff aligned. Remote CST blocks run when travel is hard; grandkids drop prompts; weekly summaries turn anecdotes into evidence. Families feel near; clinicians see trendlines they can act on.
Scale follows from design. The Method is manualised; the Institute certifies; partner sites license both and inherit the Family Peace layer. Because components are light-capex and staff-positive, growth is less about buildings and more about replication, supervision, and outcome dashboards.
The asset class emerges here: non-pharma dementia care with measured calm at a structurally lower cost base. It compounds through longer stays, lower medication use, and payer partnerships that reward avoided transfers. In short, empathy drives efficiency—and efficiency, when measured, drives investment.
"Non-pharma dementia care isn’t a nice-to-have; it’s investable. Show fewer sedative days, calmer nights, and fewer transfers—and you’ve created an asset class that pays families, clinicians, and payers."
— Linda Chang — Impact VC Partner, Singapore
Calm as a KPI
When outcomes replace anecdotes, non-pharma dementia care becomes financeable. Measure calm, shrink sedative days, prevent transfers, and keep families present. That is how better days turn into durable contracts—and why Nayuran treats empathy as a performance metric.
Clinical Rationale, Real Results
Global guidelines are clear: when agitation or psychosis appears in dementia, start with non-pharmacological care. Person-centred routines, activity, and pain review are safer first steps than sedatives. Both NICE and the APA set this order of operations, reserving antipsychotics for crisis cases. And family safety matters.
WHELD, a large UK cluster-RCT, trained staff in person-centred care and daily meaningful activity. Over nine months it improved quality of life and reduced agitation versus usual care, and did so at lower cost—small effects, big implications: better days without extra spend, and a model designed for real homes.
Beyond staff training sits Cognitive Stimulation Therapy. Across trials, CST improves cognition and quality of life, and classic economic work shows high probability of cost-effectiveness versus usual care. Maintenance CST extends gains, with cost-utility signals especially when combined with standard dementia drugs.
The safety argument is strong. Antipsychotics offer modest benefits in the short run, yet meta-analyses and regulators link them to higher mortality in older adults with dementia. The FDA’s black-box warning reshaped practice, pushing teams toward psychosocial approaches and tighter review before any prescription.
Single-modality arts therapies show mixed results for agitation, but depression often lifts and engagement rises. The most dependable signal comes when programmes combine person-centred activity, social interaction, exercise, and review. That is where agitation falls and daily life steadies without chemical restraint.
From Care to Contracts
To turn care into contracts, measure what matters. Track antipsychotic days, night episodes, CMAI agitation scores, and transfer rates. The WHELD trial demonstrated quality-of-life gains and cost savings; national evidence summaries reach the same verdict. Those metrics anchor payer pilots and scale partnerships.
Economic reviews now converge: among non-drug options, maintenance CST shows the strongest cost-effectiveness signal, with classic CST already cost-effective in early work. These are not boutique findings; they appear across community and care-home settings and map cleanly onto payer value frameworks.
Digital delivery widens access. iWHELD’s remote coaching and virtual CST groups proved feasible and beneficial in pilots, helping homes recover capacity after COVID and letting families join routines across borders. The intervention is still the same; distance simply disappears behind structured video and guidance.
Tele-assessment supports the layer above care: when speech, mood, or memory changes, validated remote tools let teams triage early. Reliable teleneuropsychology and simple remote scales cut travel and delay, keeping people in rhythm while clinicians decide if a clinic visit or medication review is truly needed.
The investor lens is straightforward. Dementia prevalence is rising toward 150+ million by 2050 and economic burden toward trillions. Programmes that deliver calmer days with fewer drugs reduce total episode costs. When those outcomes are auditable, they become investable—and contractable—at system level.
Building the Asset Class with Nayuran
Nayuran packages the evidence into an operating system. The Method blends CST blocks, movement and music, sensory cues, and family rituals; the Institute trains teams; dashboards log medication days, night episodes, and mood. Outcome language becomes daily practice, not a poster on a wall.
On the floor, caregivers run short, repeatable cycles: ten-minute social prompts, shaded walking loops, evening wind-downs, and weekly antipsychotic reviews with physicians. The point is steadiness, not heroics. Fewer crises mean calmer rosters and fewer transfers, which payers recognise as real savings.
Digital by default, human at the core: Memory Capsules and scheduled video rituals keep relatives present and staff aligned. Remote CST blocks run when travel is hard; grandkids drop prompts; weekly summaries turn anecdotes into evidence. Families feel near; clinicians see trendlines they can act on.
Scale follows from design. The Method is manualised; the Institute certifies; partner sites license both and inherit the Family Peace layer. Because components are light-capex and staff-positive, growth is less about buildings and more about replication, supervision, and outcome dashboards.
The asset class emerges here: non-pharma dementia care with measured calm at a structurally lower cost base. It compounds through longer stays, lower medication use, and payer partnerships that reward avoided transfers. In short, empathy drives efficiency—and efficiency, when measured, drives investment.
"Non-pharma dementia care isn’t a nice-to-have; it’s investable. Show fewer sedative days, calmer nights, and fewer transfers—and you’ve created an asset class that pays families, clinicians, and payers."
— Linda Chang — Impact VC Partner, Singapore
Calm as a KPI
When outcomes replace anecdotes, non-pharma dementia care becomes financeable. Measure calm, shrink sedative days, prevent transfers, and keep families present. That is how better days turn into durable contracts—and why Nayuran treats empathy as a performance metric.
Clinical Rationale, Real Results
Global guidelines are clear: when agitation or psychosis appears in dementia, start with non-pharmacological care. Person-centred routines, activity, and pain review are safer first steps than sedatives. Both NICE and the APA set this order of operations, reserving antipsychotics for crisis cases. And family safety matters.
WHELD, a large UK cluster-RCT, trained staff in person-centred care and daily meaningful activity. Over nine months it improved quality of life and reduced agitation versus usual care, and did so at lower cost—small effects, big implications: better days without extra spend, and a model designed for real homes.
Beyond staff training sits Cognitive Stimulation Therapy. Across trials, CST improves cognition and quality of life, and classic economic work shows high probability of cost-effectiveness versus usual care. Maintenance CST extends gains, with cost-utility signals especially when combined with standard dementia drugs.
The safety argument is strong. Antipsychotics offer modest benefits in the short run, yet meta-analyses and regulators link them to higher mortality in older adults with dementia. The FDA’s black-box warning reshaped practice, pushing teams toward psychosocial approaches and tighter review before any prescription.
Single-modality arts therapies show mixed results for agitation, but depression often lifts and engagement rises. The most dependable signal comes when programmes combine person-centred activity, social interaction, exercise, and review. That is where agitation falls and daily life steadies without chemical restraint.
From Care to Contracts
To turn care into contracts, measure what matters. Track antipsychotic days, night episodes, CMAI agitation scores, and transfer rates. The WHELD trial demonstrated quality-of-life gains and cost savings; national evidence summaries reach the same verdict. Those metrics anchor payer pilots and scale partnerships.
Economic reviews now converge: among non-drug options, maintenance CST shows the strongest cost-effectiveness signal, with classic CST already cost-effective in early work. These are not boutique findings; they appear across community and care-home settings and map cleanly onto payer value frameworks.
Digital delivery widens access. iWHELD’s remote coaching and virtual CST groups proved feasible and beneficial in pilots, helping homes recover capacity after COVID and letting families join routines across borders. The intervention is still the same; distance simply disappears behind structured video and guidance.
Tele-assessment supports the layer above care: when speech, mood, or memory changes, validated remote tools let teams triage early. Reliable teleneuropsychology and simple remote scales cut travel and delay, keeping people in rhythm while clinicians decide if a clinic visit or medication review is truly needed.
The investor lens is straightforward. Dementia prevalence is rising toward 150+ million by 2050 and economic burden toward trillions. Programmes that deliver calmer days with fewer drugs reduce total episode costs. When those outcomes are auditable, they become investable—and contractable—at system level.
Building the Asset Class with Nayuran
Nayuran packages the evidence into an operating system. The Method blends CST blocks, movement and music, sensory cues, and family rituals; the Institute trains teams; dashboards log medication days, night episodes, and mood. Outcome language becomes daily practice, not a poster on a wall.
On the floor, caregivers run short, repeatable cycles: ten-minute social prompts, shaded walking loops, evening wind-downs, and weekly antipsychotic reviews with physicians. The point is steadiness, not heroics. Fewer crises mean calmer rosters and fewer transfers, which payers recognise as real savings.
Digital by default, human at the core: Memory Capsules and scheduled video rituals keep relatives present and staff aligned. Remote CST blocks run when travel is hard; grandkids drop prompts; weekly summaries turn anecdotes into evidence. Families feel near; clinicians see trendlines they can act on.
Scale follows from design. The Method is manualised; the Institute certifies; partner sites license both and inherit the Family Peace layer. Because components are light-capex and staff-positive, growth is less about buildings and more about replication, supervision, and outcome dashboards.
The asset class emerges here: non-pharma dementia care with measured calm at a structurally lower cost base. It compounds through longer stays, lower medication use, and payer partnerships that reward avoided transfers. In short, empathy drives efficiency—and efficiency, when measured, drives investment.
"Non-pharma dementia care isn’t a nice-to-have; it’s investable. Show fewer sedative days, calmer nights, and fewer transfers—and you’ve created an asset class that pays families, clinicians, and payers."
— Linda Chang — Impact VC Partner, Singapore
Calm as a KPI
When outcomes replace anecdotes, non-pharma dementia care becomes financeable. Measure calm, shrink sedative days, prevent transfers, and keep families present. That is how better days turn into durable contracts—and why Nayuran treats empathy as a performance metric.